Faslodex® (Fulvestrant) — First-in-Class Selective Estrogen Receptor Degrader for HR-Positive Breast Cancer

The Only SERD That Eliminates the Estrogen Receptor — Active After Aromatase Inhibitor Failure

Faslodex® (Fulvestrant) is a selective estrogen receptor degrader (SERD) — a unique and mechanistically distinct class of antiestrogen that not only blocks estrogen receptor (ER) signalling but also targets the ER protein itself for degradation. Unlike aromatase inhibitors (Anastrozole, Letrozole, Exemestane) which reduce estrogen production, or Tamoxifen which partially blocks and partially activates ER, Fulvestrant binds to ER with high affinity, blocks all ER-mediated signalling, prevents ER dimerisation, and causes complete degradation of the ER protein — eliminating estrogen signalling at the receptor level with no residual agonist activity whatsoever.

This pure antagonist mechanism with receptor degradation makes Faslodex uniquely effective in patients whose tumours have become resistant to aromatase inhibitors — where ER mutations (particularly ESR1 mutations) or alternative ER activation pathways have rendered AI therapy ineffective. By destroying the mutated ER protein entirely, Faslodex can overcome many mechanisms of AI resistance.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Faslodex (Fulvestrant) to hospitals, oncology centres, breast cancer clinics, and pharmacies across India. Manufactured by AstraZeneca, Faslodex is an essential component of the modern HR-positive metastatic breast cancer treatment algorithm — serving as the endocrine backbone for CDK4/6 inhibitor combinations in the second-line setting and as monotherapy in selected patients.

What is Faslodex (Fulvestrant)?

Faslodex contains Fulvestrant — a steroidal antiestrogen with a unique mechanism combining complete ER antagonism with ER protein degradation. Structurally, Fulvestrant is a 7-alkylsulphinyl analogue of estradiol — it uses the natural estrogen scaffold to achieve high-affinity ER binding but carries a long hydrophobic side chain that prevents ER dimerisation, blocks coactivator recruitment, and targets the ER for proteasomal degradation.

Key mechanistic properties of Fulvestrant:

• Binds ER with approximately 100 times greater affinity than Tamoxifen
• Complete ER antagonist — no partial agonist activity unlike Tamoxifen
• Prevents ER dimerisation — blocking nuclear localisation
• Inhibits coactivator recruitment — blocking transcriptional activation
• Causes ER protein degradation through the ubiquitin-proteasome pathway
• Reduces cellular ER protein levels by 85-95%
• Active against ESR1-mutated ER — the most common mechanism of AI resistance

This combination of complete antagonism and receptor degradation is what makes Fulvestrant a true SERD — distinct from SERMs (selective estrogen receptor modulators like Tamoxifen) and aromatase inhibitors.

Full prescribing information is available at the FDA label for Fulvestrant.

Clinical Studies and Evidence

FALCON Trial (Fulvestrant 500mg vs Anastrozole — First-Line Advanced Breast Cancer) Published in The Lancet (2016), the landmark FALCON trial was the first head-to-head comparison of Fulvestrant 500mg against an aromatase inhibitor (Anastrozole 1mg) as first-line endocrine therapy for postmenopausal women with hormone receptor-positive advanced breast cancer who had not received prior endocrine therapy. Results demonstrated:

• Fulvestrant significantly improved progression-free survival — median PFS 16.6 months vs 13.8 months for Anastrozole (HR 0.797, p=0.0486)
• In patients without visceral metastases — median PFS 22.3 months vs 13.8 months — a particularly striking 8.5-month advantage
• No significant difference in overall survival — consistent with cross-over design
• Established Fulvestrant as the most active single-agent endocrine therapy for first-line HR-positive advanced breast cancer

CONFIRM Trial (Fulvestrant 500mg vs 250mg — Dose Confirmation) Published in the Journal of Clinical Oncology (2012), the CONFIRM trial was a pivotal randomised trial comparing Fulvestrant 500mg vs the originally approved 250mg dose in patients with HR-positive advanced breast cancer after prior endocrine therapy. Results:

• Fulvestrant 500mg significantly improved OS compared to 250mg — median OS 26.4 months vs 22.3 months (HR 0.81, p=0.016)
• Significantly improved PFS — median PFS 6.5 months vs 5.5 months
• Established 500mg as the definitive standard dose — replacing the previously used 250mg dose
• Confirmed that higher ER occupancy (achieved with 500mg) translates to meaningfully better clinical outcomes

PALOMA-3 Trial (Palbociclib + Fulvestrant vs Fulvestrant Alone) Published in the New England Journal of Medicine (2015), PALOMA-3 demonstrated that adding Palbociclib (Palbace) CDK4/6 inhibitor to Fulvestrant significantly improved PFS in patients with HR-positive HER2-negative metastatic breast cancer who had progressed on prior endocrine therapy — median PFS 9.5 months vs 4.6 months (HR 0.46) — one of the most dramatic PFS improvements in breast oncology at the time, establishing CDK4/6 inhibitor + Fulvestrant as the new standard of care in second-line HR-positive metastatic breast cancer.

MONALEESA-3 Trial (Ribociclib + Fulvestrant — Overall Survival) Published in the New England Journal of Medicine (2021), MONALEESA-3 demonstrated that Kryxana (Ribociclib) + Fulvestrant significantly improved overall survival compared to Fulvestrant alone in postmenopausal HR-positive HER2-negative advanced breast cancer — median OS 53.7 months vs 41.5 months — one of the longest OS benefits ever demonstrated for a CDK4/6 inhibitor + endocrine combination, firmly establishing Ribociclib + Fulvestrant as a standard of care option.

MONARCH-2 Trial (Abemaciclib + Fulvestrant — Overall Survival) The MONARCH-2 trial demonstrated Abemaciclib + Fulvestrant significantly improved OS compared to Fulvestrant alone — median OS 46.7 months vs 37.3 months — further validating Fulvestrant as the preferred endocrine backbone for CDK4/6 inhibitor combinations in the second-line setting.

BOLERO-2 and BELLE-2 Trials (Fulvestrant Combinations) Multiple trials evaluating combinations of Fulvestrant with PI3K/mTOR pathway inhibitors have confirmed Fulvestrant’s role as a versatile endocrine backbone for novel combination strategies in HR-positive breast cancer.

Available Strengths

Faslodex is available as:

Standard dose: 500mg — administered as two 5mL intramuscular injections (one into each buttock) on days 1, 15, 29, and then every 28 days thereafter. The loading doses at days 1 and 15 are essential for rapidly achieving adequate plasma Fulvestrant concentrations for effective ER suppression.

Indications — What Faslodex is Used For

As Monotherapy:

• First-line treatment of postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer not previously treated with endocrine therapy
• Treatment of postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer after disease progression on prior antiestrogen therapy

In Combination With CDK4/6 Inhibitors (Standard of Care):

• In combination with Palbace (Palbociclib) — PALOMA-3 — for HR-positive HER2-negative advanced breast cancer after prior endocrine therapy
• In combination with Kryxana (Ribociclib) — MONALEESA-3 — for HR-positive HER2-negative advanced breast cancer (first and second-line in postmenopausal)
• In combination with Abemaciclib — MONARCH-2 — for HR-positive HER2-negative advanced breast cancer after prior endocrine therapy

For detailed indication information refer to MedlinePlus Fulvestrant.

Key Benefits of Faslodex

Pure Estrogen Receptor Antagonism — No Agonist Activity Unlike Tamoxifen which has partial estrogen agonist activity on uterine and cardiovascular tissue, Fulvestrant is a pure antagonist — with no stimulatory effects anywhere in the body. This eliminates the risk of endometrial hyperplasia, endometrial cancer, and thromboembolism associated with Tamoxifen’s estrogenic effects.

ER Protein Degradation — Overcomes AI Resistance Fulvestrant’s ability to degrade the ER protein makes it effective in patients whose tumours have developed ESR1 mutations — the most common acquired resistance mechanism to aromatase inhibitors. ESR1-mutated ER remains constitutively active even in the absence of estrogen, making AIs ineffective — but Fulvestrant degrades the mutated receptor regardless of its activation status.

Superior to Anastrozole in First-Line Setting The FALCON trial establishes Fulvestrant 500mg as superior to Anastrozole in first-line HR-positive advanced breast cancer — particularly in patients without visceral disease — making it the most active single-agent endocrine therapy available.

The Preferred CDK4/6 Inhibitor Backbone in Second-Line Fulvestrant is the endocrine therapy partner of choice for CDK4/6 inhibitors in second-line HR-positive metastatic breast cancer — with proven OS benefit demonstrated in MONALEESA-3 (Ribociclib + Fulvestrant) and MONARCH-2 (Abemaciclib + Fulvestrant) — the best OS data available for any CDK4/6 + endocrine combination in this setting.

Monthly Intramuscular Dosing Monthly IM injection after loading doses simplifies treatment logistics — with clinic-administered injections ensuring adherence and providing regular clinical contact opportunities.

Established Long-Term Safety Fulvestrant has an excellent long-term safety profile — with the most common side effects being injection site reactions, hot flushes, and nausea. No increased risk of endometrial cancer, thromboembolism, or severe immunosuppression.

How Faslodex Works

Estrogen receptor-positive breast cancers depend on ER-mediated gene transcription for growth and survival. The ER signalling pathway in normal cells and tumours:

1. Estrogen binds to ER in cytoplasm
2. ER-estrogen complex dimerises and translocates to nucleus
3. ER dimer binds to estrogen response elements (EREs) in DNA
4. Coactivators are recruited to ER complex
5. Target gene transcription is activated — driving cell proliferation

Faslodex disrupts this pathway at multiple levels:

Step 1 — High-Affinity ER Binding: Fulvestrant binds to ER with approximately 100 times greater affinity than Tamoxifen — occupying the ER ligand-binding domain and preventing estrogen from binding.

Step 2 — Conformational Change Preventing Dimerisation: Fulvestrant’s bulky side chain induces a conformational change in ER that prevents the receptor from dimerising — blocking nuclear translocation and DNA binding.

Step 3 — Coactivator Exclusion: The altered ER conformation prevents recruitment of transcriptional coactivators (SRC-1, SRC-3) — blocking transcriptional activation of ER target genes even if ER reaches the nucleus.

Step 4 — ER Protein Degradation: Fulvestrant-bound ER is tagged with ubiquitin and directed to the proteasome for degradation — reducing cellular ER protein levels by 85-95%. This is the step that distinguishes Faslodex from all other antiestrogens and makes it effective against ESR1-mutated ER.

Result: Complete elimination of ER-mediated transcription — no residual agonist activity — with ER protein levels reduced to near-undetectable levels in tumour tissue.

For a detailed mechanism overview refer to Nature Reviews Cancer — SERD Mechanism and ESMO Clinical Practice Guidelines for Breast Cancer.

Faslodex vs Other Endocrine Therapies — Comprehensive Comparison

Dosage and Administration

Standard Dosing Schedule:

• Day 1: 500mg IM (two 250mg/5mL injections — one into each buttock)
• Day 15: 500mg IM (loading dose — ensures rapid achievement of steady-state plasma levels)
• Day 29: 500mg IM
• Every 28 days thereafter: 500mg IM (maintenance)

The two loading doses at days 1 and 15 are clinically important — they rapidly achieve steady-state plasma concentrations of Fulvestrant needed for maximal ER suppression. Do not omit the day 15 loading dose.

Administration Technique:

• Administer as slow intramuscular injection into gluteal muscle (buttock)
• Two 5mL injections — one into each buttock simultaneously (or sequentially)
• Use a 23-gauge 2-inch (50mm) needle for administration into gluteal muscle
• Administer slowly over 1-2 minutes per injection
• Do not administer intravenously or subcutaneously
• Allow solution to reach room temperature before injection — 30 minutes from refrigerator

Dose Modification:

• Hepatic impairment (moderate — Child-Pugh B): Reduce to 250mg (one syringe) on same schedule — days 1, 15, 29 and monthly
• Severe hepatic impairment: Not recommended
• Renal impairment: No dose adjustment required

When Used With CDK4/6 Inhibitors:

• Fulvestrant dose remains 500mg on same schedule
• Palbociclib: 125mg daily for 21 days on / 7 days off
• Ribociclib: 600mg daily for 21 days on / 7 days off
• Continue ADT (GnRH agonist) in premenopausal women when using Fulvestrant

Full dosing guidelines available at Drugs.com Fulvestrant Dosage.

Who Should Use Faslodex

Faslodex is prescribed for:

• Postmenopausal women with HR-positive HER2-negative advanced or metastatic breast cancer — first or second-line
• Patients who have progressed on aromatase inhibitor therapy — particularly those with ESR1-mutated tumours
• As the endocrine backbone for CDK4/6 inhibitor combinations in second-line HR+ metastatic breast cancer
• Patients where pure ER antagonism without uterine stimulation is clinically preferred
• Premenopausal women with advanced HR-positive breast cancer — used in combination with ovarian suppression (GnRH agonist)

Faslodex is prescribed by medical oncologists and breast cancer specialists. A.K. Pharma supplies Faslodex to hospitals, oncology centres, breast cancer clinics, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects include injection site reactions (pain, inflammation, haematoma — 10-12%), hot flushes (18%), nausea (10-14%), fatigue, elevated liver enzymes, and bone pain.

Serious but less common side effects include:

• Thromboembolic events — less frequent than Tamoxifen but possible — monitor for DVT/PE symptoms
• Hepatotoxicity — monitor liver enzymes; dose reduce in hepatic impairment
• Foetal harm — Fulvestrant is teratogenic; effective contraception essential in women of reproductive potential

Full side effect information available at FDA Fulvestrant Safety Information.

Precautions

• Not for use in premenopausal women without concurrent ovarian suppression (GnRH agonist)
• Monitor liver function tests — dose reduce in moderate hepatic impairment
• Thrombocytopenia — monitor platelet count when used with CDK4/6 inhibitors
• Bone loss — long-term endocrine therapy causes bone mineral density reduction; consider DEXA scan and bone-protective therapy
• Pregnancy — highly teratogenic; effective contraception required; discontinue if pregnancy occurs
• Avoid in severe hepatic impairment
• Refer to ESMO Breast Cancer Guidelines for complete management context

Storage and Handling

• Store in refrigerator between 2°C and 8°C
• Do not freeze — discard if frozen
• Protect from light — keep in original carton
• Allow prefilled syringes to reach room temperature before injection — approximately 30 minutes
• Single use prefilled syringes — discard after use
• Do not use if solution is cloudy, discoloured, or contains particles

As a responsible medicine distributor in Delhi, A.K. Pharma maintains full cold chain requirements during storage and supply of Faslodex ensuring product integrity for every unit supplied.

Manufacturer Information

Faslodex (Fulvestrant) is manufactured by AstraZeneca, a global biopharmaceutical company with a major oncology portfolio. Fulvestrant received FDA approval in April 2002 for advanced breast cancer, with the 500mg dose approved in 2010 and first-line indication added following the FALCON trial. A.K. Pharma supplies only genuine Faslodex sourced from authorized AstraZeneca distributors.

Related Breast Cancer Medicines Available at A.K. Pharma

• Kryxana (Ribociclib) — CDK4/6 inhibitor combined with Faslodex — MONALEESA-3 proven OS benefit
• Palbace (Palbociclib) — CDK4/6 inhibitor combined with Faslodex — PALOMA-3 standard of care
• Arimidex (Anastrozole) — aromatase inhibitor for first-line HR-positive breast cancer
• Aromasin (Exemestane) — steroidal aromatase inactivator for sequential endocrine therapy
• Zoladex (Goserelin) — ovarian suppression for premenopausal HR-positive breast cancer
• Browse all Cancer Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Faslodex used for? Faslodex (Fulvestrant) is used to treat hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer in postmenopausal women — both as monotherapy and in combination with CDK4/6 inhibitors. More information available at MedlinePlus.

Q. What is the generic name of Faslodex? The generic name of Faslodex is Fulvestrant. It is a selective estrogen receptor degrader (SERD) — a steroidal antiestrogen that completely blocks and degrades the estrogen receptor.

Q. How is Faslodex different from Arimidex (Anastrozole)? Arimidex (Anastrozole) is an aromatase inhibitor that reduces estrogen production — but the ER receptor remains intact. Faslodex directly attacks and degrades the ER receptor itself — making it effective in patients who have developed resistance to aromatase inhibitors, particularly those with ESR1 mutations.

Q. What is the correct dose of Faslodex? The standard dose is 500mg intramuscularly — given as two 250mg/5mL injections (one into each buttock) on days 1, 15, and 29, then every 28 days. The day 15 loading dose is important — do not omit it.

Q. Can Faslodex be used with CDK4/6 inhibitors? Yes — Faslodex is the standard endocrine backbone for CDK4/6 inhibitor combinations in second-line HR-positive metastatic breast cancer. Palbace (Palbociclib) + Faslodex (PALOMA-3) and Kryxana (Ribociclib) + Faslodex (MONALEESA-3) are established standard of care combinations with proven OS benefit.

Q. What is ESR1 mutation and why does it matter for Faslodex? ESR1 mutations are acquired mutations in the estrogen receptor gene that make the ER constitutively active — independent of estrogen — causing resistance to aromatase inhibitors. Faslodex degrades both wild-type and ESR1-mutated ER — making it one of the few endocrine therapies that remains active after AI resistance develops.

Q. Is Faslodex suitable for premenopausal women? Faslodex can be used in premenopausal women but must be combined with ovarian suppression using a GnRH agonist such as Zoladex (Goserelin) — to achieve postmenopausal estrogen levels before Fulvestrant can be effective.

Q. Is Faslodex available in India? Faslodex can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Faslodex in India? Faslodex 250mg price in India varies by pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Faslodex from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Faslodex in bulk? Yes. A.K. Pharma supplies Faslodex in bulk to oncology centres, breast cancer clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Faslodex from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Faslodex sourced from authorized AstraZeneca distributors
• Cold chain maintained throughout storage and delivery
• Bulk supply available for hospitals and oncology centres
• Faslodex available alongside CDK4/6 inhibitor partners — Palbace and Kryxana — simplifying procurement
• Prompt response to all quote requests
• Serving oncologists and breast cancer specialists across Delhi NCR and India

Contact A.K. Pharma for Faslodex Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in